Mark works with specialty pharmaceutical clients to provide strategic advisory services related to all aspects of mergers, acquisitions and licensing activities on a global basis. Mark works with companies throughout the development and commercialization timeline and assists with in/out-licensing and mergers and acquisitions to maximize value for the shareholders of client companies. Mark has vast experience in sourcing deals and representing clients in all aspects of deal making and negotiation in the global specialty pharmaceutical marketplace. Mark previously led business development for two specialty pharmaceutical companies (Braintree Laboratories, Inc. and Medicis Pharmaceutical Corp.) for the ten years prior to joining Triad Healthcare Partners. During that time, Mark led and completed transactions with an aggregate value of well over $1 billion. These transactions were primarily in dermatology, gastroenterology, orphan drugs and pediatrics.

Medicis Pharmaceutical Corporation (NYSE: MRX) is the leading independent specialty pharmaceutical company in the United States focusing primarily on the treatment of dermatological and aesthetic conditions.

Member of Braintree's Executive and R&D committees. Successfully completed acquisition, in-licensing, out-licensing and divestiture transactions in the US and internationally.Braintree Laboratories is a privately held, fully integrated, specialty pharmaceutical company that was founded in 1984. Braintree actively develops, distributes and markets gastroenterology products.